Cargando…

Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington’s Disease

Despite advances in understanding the pathophysiology of Huntington’s disease (HD), there are currently no effective pharmacological agents available to treat core symptoms or to stop or prevent the progression of this hereditary neurodegenerative disorder. Pridopidine, a novel small molecule compou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waters, Susanna, Tedroff, Joakim, Ponten, Henrik, Klamer, Daniel, Sonesson, Clas, Waters, Nicholas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836399/ https://www.ncbi.nlm.nih.gov/pubmed/29480206 http://dx.doi.org/10.3233/JHD-170267

Ejemplares similares

A first‐in‐human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers
por: Sjöberg, Folke, et al.
Publicado: (2021)

Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date
por: Squitieri, Ferdinando, et al.
Publicado: (2015)

Pridopidine activates neuroprotective pathways impaired in Huntington Disease
por: Geva, Michal, et al.
Publicado: (2016)

Metoprolol‐pridopidine drug–drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease
por: Rabinovich‐Guilatt, Laura, et al.
Publicado: (2017)

Altered pattern of brain dopamine synthesis in male adolescents with attention deficit hyperactivity disorder
por: Forssberg, Hans, et al.
Publicado: (2006)

The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease
por: Rabinovich‐Guilatt, L., et al.
Publicado: (2015)

Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
por: Svenningsson, Per, et al.
Publicado: (2018)

Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Chen, Shujun, et al.
Publicado: (2021)

Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model
por: Squitieri, Ferdinando, et al.
Publicado: (2015)

Pridopidine Reverses Phencyclidine-Induced Memory Impairment
por: Sahlholm, Kristoffer, et al.
Publicado: (2018)

Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis
por: Estévez‐Silva, Héctor M., et al.
Publicado: (2022)

Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose
por: Darpo, Borje, et al.
Publicado: (2023)

Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [(18)F] fluspidine and [(18)F] fallypride PET study
por: Grachev, Igor D., et al.
Publicado: (2020)

Pridopidine Promotes Synaptogenesis and Reduces Spatial Memory Deficits in the Alzheimer’s Disease APP/PS1 Mouse Model
por: Estévez-Silva, Héctor M., et al.
Publicado: (2022)

A Rationale for Hypoxic and Chemical Conditioning in Huntington’s Disease
por: Burtscher, Johannes, et al.
Publicado: (2021)

Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease
por: Francardo, Veronica, et al.
Publicado: (2019)

Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study
por: McGarry, Andrew, et al.
Publicado: (2020)

The Pathophysiology and Pharmacological Treatment of Huntington Disease
por: Pidgeon, Connie, et al.
Publicado: (2013)

Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma
por: Geva, Michal, et al.
Publicado: (2021)

Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses
por: Sahlholm, Kristoffer, et al.
Publicado: (2015)

Current Pharmacological Management in Juvenile Huntington’s Disease
por: Robertson, Lisa, et al.
Publicado: (2012)

Current Pharmacological Approaches to Reduce Chorea in Huntington’s Disease
por: Coppen, Emma M., et al.
Publicado: (2016)

An Overview of Potential Targets for Treating Amyotrophic Lateral Sclerosis and Huntington's Disease
por: de Paula, Caroline Zocatelli, et al.
Publicado: (2015)

Rationale for Further Development of a Vaccine Based on the Circumsporozoite Protein of Plasmodium vivax
por: Yadava, Anjali, et al.
Publicado: (2017)

An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington’s Disease
por: Burgunder, Jean-Marc, et al.
Publicado: (2011)

An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease
por: Groves, Mark, et al.
Publicado: (2011)

Studying Huntington’s Disease in Yeast: From Mechanisms to Pharmacological Approaches
por: Hofer, Sebastian, et al.
Publicado: (2018)

Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine
por: Wang, Shao-Ming, et al.
Publicado: (2022)

Recent Overview of the Use of iPSCs Huntington’s Disease Modeling and Therapy
por: Csobonyeiova, Maria, et al.
Publicado: (2020)

Lactobacillus rhamnosus GG: An Overview to Explore the Rationale of Its Use in Cancer
por: Banna, Giuseppe L., et al.
Publicado: (2017)

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse
por: Kusko, Rebecca, et al.
Publicado: (2018)

Targeting the autophagy-lysosomal pathway in Huntington disease: a pharmacological perspective
por: Yang, Junsheng, et al.
Publicado: (2023)

Pharmacology and rationale for imatinib in the treatment of scleroderma
por: Moinzadeh, Pia, et al.
Publicado: (2013)

Irritability in Huntington’s Disease
por: Karagas, Nicholas E., et al.
Publicado: (2020)

Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1(G93A) Model
por: Ionescu, Ariel, et al.
Publicado: (2019)

An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington’s Disease
por: Anderson, Karen, et al.
Publicado: (2011)

Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease
por: Pineda, Jose R, et al.
Publicado: (2009)

HTT haplogroups in Finnish patients with Huntington disease
por: Ylönen, Susanna, et al.
Publicado: (2019)

Huntington's disease protein extends its reach
por: Leslie, Mitch
Publicado: (2008)

Huntington disease: Advances in the understanding of its mechanisms()
por: Gatto, Emilia M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9dn7r2fe2kcg9n5behbvd4fcpp